surpass-2 tirzepatide vs semaglutide weight loss Efficacy of versus in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the Trial | Diabetologia SURPASS 2: Tirzepatide Versus Once-Weekly

Malnutrition in obesity is serious and under researched

Pregnancy: not recommended

For example, some data suggests that semaglutide can modulate the levels of thyroxine (T4) and triiodothyronine (T3), the two significant hormones produced by the thyroid gland

the main side effects (nausea, reduced appetite, mild GI symptoms) are dose-related, not schedule-related

This breakthrough helps individuals struggling with obesity improve overall health and reduce disease risk

This system does not require the expression of toxic exogenous Cas9, resulting in a significant improvement in transformation efficiency, further expanding the toolkit for genetic modifications in this challenging organism [112]